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Introduction
Although not necessarily a new concept, since its designation by Sackett et al in 1996, 
evidence-based medicine (EBM) has become a watchword for the medical commu-
nity. EBM is the term applied to the application of the scientiﬁ  c method to medical 
practice and involves the direct application of the best-available medical research data 
to clinical patient care. It requires the integration of available research evidence with 
clinical experience and may challenge long-standing medical traditions that have not 
yet been subjected to appropriate scientiﬁ  c scrutiny. Among clinical providers from 
various medical specialties there is a growing awareness of the importance of applying 
EBM in health care settings (Hagdrup et al 1998; Stefanski et al 2004; Luehr 2006). 
Whether providers are making the transition from realization to application, however, 
remains equivocal (Benatar 2005) or unknown (Robinson et al 2004).
The emerging appreciation of EBM is also recognized within the ophthalmic 
literature (Sharma 2001; Straatsma 2003) as well as by the International Council of 
Ophthalmology (2007). The appearance of various letters to ophthalmic journal editors 
also suggests that clinicians realize the shortcomings inherent in the reported ﬁ  ndings 
for diverse ophthalmic clinical trials involving “normal-tension” glaucoma (Caprioli 
and Maguire 2001), neovascular age-related macular degeneration (Spaide 2006), 
and dry eye syndrome (Brown 2007), just to name a few. Additionally, ophthalmic 
investigators and providers are aware of differences that arise between analogous tri-
als – eg, the Ocular Hypertension Treatment Study (OHTS) (Kass et al 2002) and the 
European Glaucoma Prevention Study (EGPS) (EGPS Group 2005) – and are actively 
seeking to understand these differences.
However, most medical providers continue to offer clinical recommendations to 
patients based on didactic instruction, clinical lore, or habit because of the continuing 
frustration faced when trying to reconcile the necessity to review an overwhelming 
amount of published medical information within the time limitations of daily practice 
(Barton 2001). As succinctly stated by Lee, when it comes to medical knowledge 
“there is simply too much to know” (Lee 2005).
With respect to medical literature, there is a common fallacy that faces reviewers: 
that if a recommendation appears in print, it must be valid (ie, a form of assumption Clinical Ophthalmology 2008:2(2) 402
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bias on the part of the reader). This form of bias occurs 
when journal reviewers under time constraints quickly scan 
abstracts and assume that the statements provided in the 
“conclusion” section must be accurate and backed up by the 
following pages of the article and the accompanying refer-
ences (ie, written word bias). Another form of assumption 
bias may be found in the belief that the contents of expert 
speaker lectures or recommendations from pharmaceutical 
company representatives are entirely objective and lacking 
bias (authority bias).
Unfortunately, these assumptions are not always true. 
Although not explicitly stated during professional training, all 
healthcare providers are expected to provide their own self-
education once they leave their institutions of graduate learn-
ing. This means continually reviewing pertinent journals, and 
then completing the Herculean task of critically evaluating 
the literature, dismissing incomplete data and applying new 
information directly to patient encounters. Through this 
process the implicit, underlying belief is that clinicians will 
continue to grow in knowledge, thereby becoming better, 
more-informed clinicians as they accumulate more clinical 
experience based on EBM. At no time would a medical 
professional be expected to be the same provider that he 
or she was a year previously. This would seem to be the 
expectations of patients as well (Lee 2005) and enters into 
the controversial side issues of ongoing provider competency 
(American College of Physicians 2004).
Fortunately, there are now online open-access resources 
available to disseminate EBM: The Cochrane Collabora-
tion (www.cochrane.org/index0.htm) and Bandolier (www.
jr2.ox.ac.uk/bandolier/), among others. Also, clinical trial 
registry is now required prior to publication of results of 
trials in some journals (http://clinicaltrials.gov/), which may 
help to prevent non-publishing of negative results of some 
clinical trials.
Quite simply, the consequences of failing to review 
the literature critically are untoward morbidity and mortal-
ity for patients. The literature is replete with examples of 
failed medical therapies once heralded as being deﬁ  nitive: 
intracranial-extracranial arterial bypass to reduce the risk of 
ischemic stroke (EC-IC Bypass Study Group 1985), anti-
inﬂ  ammatory therapy with rofecoxib (Vioxx®, Merck and Co 
Inc, Whitehouse Station, NJ, USA) therapy (Bresalier et al 
2005), and use of oral prednisone as monotherapy in patients 
with optic neuritis (Beck et al 1992). Chalmers statement that 
“One only has to review the graveyard of discarded therapies 
to discover how many patients have beneﬁ  ted from being 
randomly assigned to a control group” (1968) reminds us that 
all providers should be even more diligent about experimental 
therapies and critical of the results of the reports. Finally, 
providers cannot rely on the existing mechanisms of public 
oversight groups to ensure that reported clinical trial results 
are wholly trustworthy (Topol 2004).
The unwritten corollary of these expectations is that cli-
nicians will provide the ultimate control over new medical 
practices, procedures, and pharmaceutical products entering 
the health care marketplace. In other words, sceptical review 
of medical literature by practitioners with the null hypothesis 
ﬁ  rmly in mind (ie, there is no difference between treatment 
groups) and assessing the consistency of results with personal 
observations would satisfy the demands of EBM and avoid 
introduction of sub-optimal treatments and agents into daily 
practice. However, practitioners continue to make clinical 
recommendations based on peer consultation, expert opinion 
provided at continuing medical education conferences, or (as 
can be the case with pharmaceutical agents) based on data pro-
vided by representatives of pharmaceutical corporations.
The business of pharmaceutical 
clinical trials
To understand the impetus behind this process, practitioners 
must realize the ﬁ  nancial implications of bringing a new 
pharmaceutical agent to the marketplace. The estimated 
cost for the discovery, development, experimental trial and 
introduction of a single, new, successful drug to the market-
place ranges from approximately  277 million ($390 million; 
Kettler 1999 [estimates updated to 2007 values via inﬂ  ation 
calculator]) to  568 million ($800 million; Pharmaceutical 
Research and Manufacturers of America 2007). Of this total, 
slightly less than 50% is incurred in the execution of clinical 
pharmaceutical trials (Kettler 1999).
In terms of global expenditures for pharmaceutical research 
and development, the top ﬁ  fty pharmaceutical companies 
on the planet spent an estimated  62 billion in 2006 alone 
(MedAdNews 2007). In order to provide a broader  frame of 
reference, bear in mind that this sum for research and devel-
opment expenditures would rank the pharmaceutical industry 
number 56 out of 180 in a world ranking of countries by Gross 
Domestic Product (International Monetary Fund 2007).
By contrast, publicly-funded (government) spending on 
pharmaceutical research lags considerably behind private 
sector spending. The US government invested approximately 
7 billion ($10 billion) per year in pharmaceutical research 
and development in the 1990s (Congressional Budget Ofﬁ  ce 
2006), and the EU estimates for pharmaceutical research 
funding was expected to be approximately  0.5 billion Clinical Ophthalmology 2008:2(2) 403
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per year between 2002 and 2006, which represented a 
doubling of expenditures over the previous four years 
(European Commission 2002). Contrast these ﬁ  gures to the 
21 billion ($29.9 billion) spent annually on pharmaceutical 
promotion to the public via direct-to-consumer campaigns 
(Donohue 2007). In summary, an enormous amount of money 
is spent each year on pharmaceutical research and private 
industry is funding the bulk of it.
Literature review
Within this environment of colossal ﬁ  nancial pressure to 
realize returns on investments, the potential for bias in phar-
maceutical trial conduct and reporting remains real and is 
recognized in the medical literature (Als-Nielsen et al 2003; 
Liesegang et al 2005). Thus, the pertinent question remains: 
how can clinicians obtain objective knowledge regarding 
novel pharmaceutical agents? The answer, of course, is by 
developing an awareness of this problem and addressing it 
through continuous, careful review of medical literature. 
Again, formal training for healthcare providers offers very 
little in the way of teaching methods for critical literature 
review, which is necessary to achieve this end. Furthermore, 
with the explosion of medical research publication that was 
taking place by the 1980s, it became clear that providers 
were unable to keep up with the deluge of new information 
that they were facing. Across all medical disciplines over 11 
million randomized controlled trials had been recorded via 
MEDLINE by 2001 (Tsay and Yang 2005).
More germane to eye care, according to MedBioWorld 
there are more than 80 journals dedicated exclusively to eye 
and vision research (2007). In 2006 the Cochrane Eyes and 
Vision Group tallied more than 5,000 ophthalmic clinical 
trials in just 7 different ophthalmic journals accounting 
for 125 years of cumulative publications; while in 2004 
alone, there were 1,919 articles published in 4 leading 
ophthalmology journals (Lai et al 2006).
In order to provide some structure to clinical trial 
review, various medical journals have provided methods 
for systematic literature reviews with the goal of teaching 
these techniques to their readers (Evidence-Based Medicine 
Working Group 1993–2000; Sackett et al 1997; Glasser 
and Howard 2006; Ives 2006). These reviews provide good 
points of departure when learning or teaching critical litera-
ture review.
Statistical discussions contained in clinical trial reports 
can also appear overwhelming. Not all clinicians can hold 
advanced mathematics degrees in statistics in order to 
fully interpret the signiﬁ  cance of applied methods for Cox 
regression models, paired-eye correlation techniques, and 
non-parametric bootstrap procedures (examples from only 
the Advanced Glaucoma Intervention Study trial 2004); 
however, distilling the presented trial data into useful clinical 
information is an EBM skill incumbent upon all providers. 
Number-needed-to-treat analysis is a relatively straightfor-
ward mathematical application to help clinicians who are 
non-statisticians (McQuay and Moore 1997).
A general framework for critically appraising any clinical 
trial can be organized under four general headings: (1) has the 
study been appropriately designed? (2) Have the study results 
been correctly analyzed? (3) Have the study results been 
interpreted correctly? (4) Can the study results be applied 
to the patients in the reviewer’s practice? (Ives 2006). A 
more detailed summary of questions to ask when reviewing 
pharmaceutical (or other clinical) trial data is provided in 
Table 1. For further in-depth discussions of the speciﬁ  cs of 
clinical trial design (ie, randomization schemes, determina-
tion of n values, alpha calculations, statistical power, etc) 
please consult appropriate references.
Clinical trial validity and bias
When assessing EBM, reviewers of clinical trial data must 
consider internal and external validity of the clinical trial 
results. When internal validity is met, readers can be assured 
that the study has truly examined what it set out to measure. 
The majority of the questions in Table 1 address this com-
ponent. External validity is the ability to generalize ﬁ  ndings 
from the study cohort to the general population and will be 
discussed in turn.
In order to determine study validity, readers must ﬁ  rst 
consider potential sources of error in the study. Essentially 
all medical studies contain varying degrees of bias (Grimes 
and Schulz 2002), which is considered to be: “any trend in 
the collection, analysis, interpretation, publication or review 
of data that can lead to conclusions that are systematically 
different from the truth” (US Centers for Disease Control 
and Prevention 2006). The presence of bias is controlled 
via careful study design and statistical analysis; however the 
complete elimination of all forms of bias may still be unat-
tainable. The presence of bias does not automatically imply 
that the study results should be disregarded, however, the 
ﬁ  nal acceptance of study results ultimately resides with the 
reader, who must balance potential sources of bias against 
their possible impact on the recommendations and conclu-
sions of the authors, and secondary interpretations by experts. 
Once more, the onus for change in clinical practices based 
on EBM lies with the provider.Clinical Ophthalmology 2008:2(2) 404
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There are over one hundred recognized types of bias in the 
medical literature (Armitage and Colton 2005). Although there 
is no consensus regarding a set number of “major” sources of 
bias, experimental errors can be loosely considered to occur 
during three periods: before the study begins (selection bias), 
while the data is being collected during the study (information 
bias), and after the conclusion of the study period when data 
interpretation occurs (interpretation bias). (For further discus-
sion regarding sources of research bias see also: Rothman and 
Greenland 1998; Grimes and Schultz 2002; Chow and Liu 
2003, among many others.) For ophthalmic pharmaceutical 
trials, careful attention must be paid to the effects of selec-
tion bias and will be the focus of the following discussion. 
Speciﬁ  cally, a review of patient selection criteria, standards of 
comparison, and meeting well-deﬁ  ned endpoints are areas of 
potential selection bias in some ophthalmic clinical trials.
Patient selection
Based on a review of existing literature, the issue of bias 
in patient recruitment for inclusion into ophthalmic studies 
has not been directly addressed. Nor have the effects of 
volunteer bias (study volunteers tend to be healthier than 
non-participants and may exhibit outcomes unlike other 
subjects) or study remuneration (another form of volunteer 
bias) for participation in ophthalmic studies.
Patient recruitment
Bias in the recruitment of controls for comparison to affected 
study participants would not seem to be an issue for many 
advanced-stage ophthalmic pharmaceutical trials. Presum-
ably because at this point in the process (ie, Phase 3 trials in 
the US), investigational medications are typically used only 
on those patients who already manifest a given condition for 
which there is no deﬁ  nitive treatment (ie, healthy human sub-
jects in a control group are not given experimentally-induced 
choroidal neovascular membranes or intraocular pressure 
increases in order to test efﬁ  cacy of experimental pharma-
ceutical agents). In general, these trial subjects are recruited 
directly from patient encounters in participating study sites as 
they are diagnosed clinically, and appropriate randomization 
schemes are used to prevent unexpected differences between 
cohorts. However, reviewers should be aware that there are 
many industry-sponsored pharmaceutical trials that actively 
recruit patients and remunerate for their participation (Center 
Watch 2007). The reader is left to attend to study sponsorship 
and to discern whether volunteer bias could account for small 
discrepancies in reported treatment effects.
In one of the ﬁ  rst efﬁ  cacy studies for olopatadine hydro-
chloride (Patanol®), patients with a prior history of active 
allergic conjunctivitis were required to have positive derma-
tological (skin prick), serological (radioallergosorbent test 
[RAST]), or conjunctival test for enrolment into the study 
(Abelson and Spitalny 1998). To remain enrolled in the study, 
participants were required to have a positive conjunctival 
allergen challenge (CAC) at subsequent visits. CAC testing 
requires provocative inoculation of eyes with increasing aller-
genic inoculations, assessing for allergic responses, and then 
evaluating ocular responses to trial medications (Abelson 
et al 1990). CAC testing provides highly reproducible 
results and has been used frequently when studying groups 
of human ocular allergies (Friedlaender 2004), although 
questions remain regarding individual responses (Aichane 
et al 1993) and use of rescue medications and quality of 
life issues (Radcliff et al 2006). Few clinicians have direct 
clinical experience with CAC testing and may be left with 
lingering questions regarding the generalised applicability 
of CAC testing and the results of such trials. The result may 
be reliance on the opinions of others. However, clinicians 
Table 1 Questions to ask when reviewing a clinical trial
Has the study been appropriately designed?
1.  Who did the study?
2.  At what sites was the study performed? (ie, was it multicentered?)
3.  Who sponsored the study?
4.  What is the null hypothesis?
5.  Why is this question clinically important?
6.  Were endpoints speciﬁ  c and achievable?
7.  Does the study provide in vitro or in vivo data?
8.  Was the study appropriately randomized?
9.  Was there a control or gold standard group?
10.  Were study investigators and subjects double-masked?
11.  Was there an adequate sample size?
12.  Were the groups similar at the beginning of the study?
13.  Was the length of the study adequate?
Have the study results been correctly analyzed?
14.   Were all of the study subjects accounted for at the end of the 
study?
15.  What was the dropout rate for subjects?
16.  What were the investigators’ conclusions?
Have the study results been interpreted correctly?
17.  Are the results given in terms of the stated, primary outcomes?
18.  Do the data agree with the conclusions?
19.  Are there any confounding variables?
20.  Do you agree with the results?
Can the study results be applied to the patients in the 
reviewer’s practice?
21.  Should you abandon the gold standard?
22.  Are the results generalisable to wider populations?
23.  Were there any incidental ﬁ  ndings?
24.  Were there any unanswered questions raised by the study?Clinical Ophthalmology 2008:2(2) 405
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are reminded that questions regarding patient recruitment, 
olopatadine and EBM have not been deﬁ  nitively answered 
in the literature (especially with respect to a gold standard 
for allergic conjunctivitis discussed below).
Eligibility (inclusion and exclusion) 
criteria
Ophthalmic providers must recognize that certain inclusion and 
exclusion criteria for clinical trials may create other forms of 
internal bias that can affect external validity of reported results. 
This in turn may explain differences between the responses 
of patients reported in studies to those observed in non-study 
site clinics (ie, a failure to demonstrate external validity). 
Unfortunately, there are many ophthalmic clinical trials that 
leave unanswered questions for the reader to ponder.
For example when considering a study of ocular hyper-
tension or open-angle glaucoma (OAG), there is a ques-
tion as to whether the inclusion of patients with secondary 
open-angle glaucoma forms (eg, pseudoexfoliation [PXG] or 
pigmentary dispersion glaucoma [PDG]) affect the outcomes. 
When exact etiologies remain unknown, reviewers cannot be 
certain that it will not. Furthermore, results from one racial 
population may not necessarily translate to similar ﬁ  ndings 
in other racial groups.
In neovascular age-related macular degeneration (AMD), 
questions remain as to whether occult, classic, and mixed 
forms of choroidal neovascular membranes (CNVM) follow 
the same natural progression. Conversion between types is 
known to occur. Conversely, do patients with recurrent cho-
roidal revascularization respond differently to an intervention 
than those with primary lesions? Clinical experience suggests 
that they do in some cases.
For ophthalmic complications of diabetes mellitus, the 
question arises as to whether patients in a study of clinically-
signiﬁ  cant macular oedema (CSME) respond differently than 
those with non-CSME. Perhaps more to the point, why treat 
those patients previously described as being “non-clinically 
signiﬁ  cant”? In addition, it is not clear whether subjects will 
have equivalent responses to a treatment if there is an isch-
emic macula versus a normally-perfused macula, and what 
if those patients retain good visual acuity at the outset? Does 
the duration of the macular oedema affect the outcomes?
Finally, can the results of a study targeting primarily 
female patients be applied to a clinical population which also 
includes males, or even predominantly males as in the case of 
an American Veterans’ Health Administration eye clinic?
Speciﬁ  c examples of these types of potential selection 
bias regarding eligibility criteria observed in ophthalmic 
studies are presented in Table 2. Certainly other questions that 
arise from clinical trial review exist as well. It is also impor-
tant to bear in mind that most patients in these studies were 
excluded from having other ocular co-morbidities such as 
cataracts, subnormal vision, prior ophthalmic surgeries, and 
the like. Patients with co-morbid conditions may or may not 
respond to treatments in the same way, further questioning the 
issue of external validity of the studies. While generalization 
from single morbidity patients to co-morbid ones has been 
discussed in other medical disciplines (eg, primary care) 
(Fortin et al 2006), to date it has not been directly addressed 
for ophthalmic patients.
If the natural courses of the disease for subtypes of patients 
are etiologically identical, then it is acceptable to combine 
sub-groups for statistical analysis. However, the authors should 
point out these differences (if they exist) and, likewise, the 
Table 2 Clinical studies with uncertain inclusion/exclusion criteria
Pharmaceutical intervention  Selection criteria  Reference
Hypotensive eye drops vs surgery  Inclusion of PXG/PDG pts in OAG study  Lichter et al 2001
Laser/eye drops vs observation  Inclusion of PXG pts in OAG study  Heijl et al 2002
Ranibizumab for AMD  Inclusion of AMD subtypes (occult, classic, mixed)  Heier et al 2006
Anecortave acetate for AMD  Inclusion of primary and recurrent CNVM  Schmidt-Erfurth et al 2005
Pegaptanib sodium for DME  Inclusion of non-CSME patients in cohort  MDRSG 2005
Bevacizumab for DME  Inclusion of ischemic and non-ischemic maculae  Arevalo et al 2007
Triamcinolone acetonide for DME  Inclusion of patients with CSME of unknown duration  Jonas et al 2005
Hypotensive eye drops vs observation  Incidental exclusion of non-white racial groups  EGPS Group 2005
Triamcinolone acetonide for DME  Exclusion of patients with poor visual acuity  DRCRN 2007
Cyclosporine for dry eye syndrome  Exclusion of signiﬁ  cant number of male patients  Sall et al 2000
Pharmaceuticals: ranibizumab (Lucentis®, Genentech Inc, South San Francisco, CA, USA); anecortave acetate (Retaane®, Alcon Research LTD, Fort Worth, Texas, USA); 
pegaptanib sodium (Macugen®, [OSI] Eyetech Pharmaceuticals Inc, New York NY, USA); bevacizumab (Avastin®, Genentech Inc, South San Francisco, CA, USA); cyclosporine 
(Restasis®, Allergan, Irvine, CA, USA).
Abbreviations: AMD, age-related macular degeneration; CNVM, choroidal neovascular membranes; CSME, clinically signiﬁ  cant macular oedema; DME, diabetic macular 
oedema; MDRSG, Macugen Diabetic Retinopathy Study Group; DRCRN, Diabetic Retinopathy Clinical Research Network; EGPS, European Glaucoma Prevention Study; OAG, 
open-angle glaucoma; OCT, optical coherence tomography; PDG, pigmentary dispersion glaucoma; PSG, pseudoexfoliation.Clinical Ophthalmology 2008:2(2) 406
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reader should be aware that these differences could inﬂ  uence 
the stated ﬁ  ndings and explain differences between reported 
and observed outcomes. Consider the combination of CNVM 
data from AMD and Myopia in the TAP and VIP Reports 
(2003); and question whether it would also be appropriate to 
apply these results to cases of idiopathic CNVM.
The review of medical literature suggests other problems 
inherent in patient selection: failure of study investigators 
to invite eligible patients to participate in studies (Amiel 
et al 2007), potential inﬂ  uencing of patients by investigators 
toward inclusion/exclusion from a study (Engel et al 2006), or 
exclusion of potential subjects due to socioeconomic factors 
(Rahi et al 2004), just to mention a few. Readers should be 
aware of these, and other, potential shortcomings and care-
fully examine the methods of recruiting patients for entry 
into clinical trials.
Standards of comparison
When considering the performance of a pharmaceutical 
agent, a proper frame of reference must be utilized by study 
investigators. Reviewers of clinical trials should be aware 
when studies lack solid standards of comparison or when 
other factors cloud direct comparisons between groups. It 
is also worthy of note that not all trials that deﬁ  ne the same 
clinical endpoint are identically designed, so direct com-
parison of resultant ﬁ  ndings can be potentially misleading. 
Additionally, trials assessing the same outcomes may include 
patients at different stages of the disease. In sum, the study 
must not compare metaphorical “apples” to “pears”.
Insufﬁ  cient patient numbers
Strength of clinical trial results often depends on the number 
of study subjects. Insufﬁ  cient patient numbers lead to weak 
associations; too many patients no longer adds to statisti-
cal power. In general, the number of patients enrolled in 
a study is based upon the suspected treatment effect (ie, if 
investigators expect a 20% difference between groups, then 
x number of patients are recruited; if the expectation is 30%, 
then y number of patients are enrolled, and so on). In gen-
eral, the narrower the expected treatment margin, the larger 
the number of patients required to statistically demonstrate 
that difference (Beck 2006). Because of the variance in dis-
ease incidences, there is no accepted minimum number of 
patients required in order to statistically power a study. For 
pharmaceutical trials, the US Food and Drug Administration 
(FDA) recommends that Phase 3 trials (ie, those designed 
to ensure safety and efﬁ  cacy before pharmaceutical release 
for use by the general population) enrol “several hundred to 
several thousand” patients (FDA 2007) to ensure validation 
of clinical trial data. Because of the strict controls involved 
in these trials, Phase 3 trials results should be rigorously 
scrutinized, and their outcomes seriously considered, prior 
to the integration of a new agent into clinical practice. 
Conversely, readers should be aware that Phase 3 trials are 
also industry-sponsored and that some Phase 3 data remain 
unpublished and tightly guarded due to proprietary interests 
(yet another source of potential bias).
When studies fail to enrol a signiﬁ  cant number of patients, 
then small differences in study groups can lead reviewers 
to question slim margins of successful treatment. There are 
many pharmaceutical studies with low numbers of partici-
pants. The Phase 3 study for Patanol® enrolled 169 patients 
in three arms (Abelson and Spitalny 1998), whereas the 
Verteporﬁ  n in Photodynamic Therapy (VIP Study Group 
2001) examined 120 patients in two arms and the Collabora-
tive Normal-Tension Glaucoma Study (1998, not a Phase 3 
pharmaceutical study) enrolled 140 patients in 2 trial arms. 
Readers should bear in mind that the n value represents the 
total number of study participants (or eyes, depending on the 
study), and that the ﬁ  nal number of patients in each arm of 
the study will be reduced accordingly.
Failure to compare against the 
“gold standard”
If a new therapeutic agent is recommended for integration 
into current disease management plans, how can clinicians 
be assured that the recommendation is valid if the agent in 
question has not been compared against the gold standard 
treatment for that condition? Originally, the term gold 
standard applied to a diagnostic test that was considered to 
be deﬁ  nitive in its determination of a condition. However, 
in more recent times, the phrase has come to represent any 
medical benchmark (clinical outcome, diagnostic test, biopsy, 
chronic disease index, medication, autopsy, etc) against 
which new procedures and tests can be measured. There are 
many ophthalmic gold standards ranging from clinical test-
ing for malingering (Gundogan et al 2007) and automated 
perimetry for glaucoma (Thomas and George 2001) to com-
puterized tomography for suspected orbital fractures (Cruz 
and Eichenberger 2004) and reference stereo photographs 
for grading diabetic retinopathy (Williams et al 2004). In 
essence, ophthalmic providers are well aware of certain clini-
cal practices against which others are compared.
This being the case, a gold standard retains its place 
of prominence until a new test, medication, or procedure 
challenges its status and there is widespread conﬁ  rmation via Clinical Ophthalmology 2008:2(2) 407
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research data that there is a new gold standard. Unfortunately, 
there is no governing medical body to oversee these transitions 
and the metamorphosis may take years for providers (consider 
the apparent low impact of the results of the optic neuritis 
treatment trial [Trobe et al 1999]). With regard to pharma-
ceutical agents, in the absence of a widely-accepted gold 
standard, researchers may need to compare an intervention 
to nothing (ie, the natural course of the disease) or a placebo, 
which will be discussed below. Table 3 lists a few studies that 
have abandoned important ophthalmic gold standards.
Readers should also be aware of the importance of unex-
pected ﬁ  ndings when head-to-head comparisons with gold 
standards do periodically occur. In the only randomized clini-
cal trial of an ophthalmic fourth-generation ﬂ  uoroquinolone 
since US approval in 2003, moxiﬂ  oxacin (Vigamox®, Alcon 
Research LTD, Fort Worth, TX, USA) was found to be an 
equivalent – but not superior – therapy for bacterial corneal 
ulcers when compared to the anti-bacterial gold standard: 
fortiﬁ  ed topical anti-bacterial solutions or an older amino-
glycoside (Constantinou et al 2007).
The results of the only study comparing olopatadine 
hydrochloride to a mild ophthalmic steroid showed superior-
ity of olopatadine; however, the comparison was not made to 
a classic corticosteroid like dexamethasone, ﬂ  uorometholone 
or prednisolone, but rather to a newer, ophthalmic corticoste-
roid, loteprednol etabonate (Lotemax®, Bausch and Lomb, 
Tampa, FL, USA; Berdy et al 2002). Prior to the introduction 
of olopatadine, gold standard treatment for allergic conjunc-
tivitis was single-action ophthalmic antihistamine or steroid 
eye drops (Spalton 1984).
In the case of CNVM related to AMD, neither verte-
porﬁ  n, pegaptanib, ranibizumab or bevacizumab have been 
compared to thermal laser photocoagulation, the previous 
gold standard for these cases. Interestingly, when sub-
macular surgery was compared to laser photocoagulation 
no advantage to incisional surgery was found, the negative 
results were reported (Submacular Surgery Trials pilot Study 
Investigators 2000), and interest in the procedure waned as 
should be expected.
However, reviewers are left to wonder why the anti-
bacterial comparison to the gold standard was so slow in 
coming and why the anti-allergy trial did not compare the 
study medication to the older gold standard. Neither of these 
questions remains answered. Even bigger questions remain 
regarding why ophthalmic practitioners so quickly converted 
prescribing patterns in favor of the newer medications.
Failure to compare to placebo
The placebo effect on medical studies has been well docu-
mented for many years, yet it remains poorly understood and 
its overall effect varies among trials. However, the inherent 
problems in comparing a pharmaceutical agent to baseline 
performance (ie, nothing) are also widely recognized and the 
failure to include placebo control may introduce a signiﬁ  cant 
source of bias to study outcomes. An excellent example of the 
failure to include placebo control is the Ocular Hypertension 
Treatment Study (OHTS, Kass 2002). OHTS investigators 
were attempting to compare the treatment of ocular hyperten-
sion to controls who received no placebo treatment. Because 
the results of this study were not unequivocal, a reviewer 
must ask if the results had been different (or the treatment 
effect even narrower than what was reported) had the control 
group received placebo treatment. The lack of placebo control 
leaves room for doubt in the results of a clinical trial that has 
generated so much attention since its publication.
There is cause for concern when pharmaceutical studies 
for bacterial keratitis are not placebo-controlled. Although 
terminology is likely a barrier to understanding in this 
instance (ie, superﬁ  cial keratitis versus corneal ulceration, or 
the use of the term “microbial” keratitis, requiring readers to 
determine which microscopic organism is being discussed), 
it is generally conceded that non-ulcerative bacterial keratitis 
Table 3 Clinical studies not addressing established ophthalmic gold standards
Pharmaceutical intervention  Reference  Gold standard  Gold standard
    reference
Verteporﬁ  n for AMD  TAP 1999  Thermal laser photocoagulation  MPS 1991
  TAP 1999  Geographical Criteria for CNVMa MPS  1991
Pegaptanib sodium for DME  MDRSG 2005  CSME  ETDRS 1991
Triamcinolone acetonide for DME  DRCRN 2007  OCT in lieu of CSME  ETDRS 1991
Olopatadine for ocular allergies  Abelson 1998  Mild corticosteroid  Spalton 1984
aie, subfoveal, juxtafoveal and extrafoveal.
Pharmaceuticals: verteporﬁ  n (Visudyne®; Novartis AG, Basel, Switzerland).
Abbreviations: AMD, age-related macular degeneration; CNVM, choroidal neovascular membranes; TAP, Treatment of Age-related Macular Degeneration with Photodynamic 
Therapy Study Group; MPS, Macular Photocoagulation Study Group; ETDRS, Early Treatment Diabetic Retinopathy Study Research Group; DRCRN, Diabetic Retinopathy 
Clinical Research Network; CSME, clinically signiﬁ  cant macular oedema; OCT, optical coherence tomography.Clinical Ophthalmology 2008:2(2) 408
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(ie, a mild superﬁ  cial keratitis) is a self-limiting condition 
(Chung and Cohen 2000; Sheikh and Hurwitz 2001; Epling 
and Smucny 2006). Readers should be wary of lack of 
placebo control in some of these studies when reviewing 
head-to-head comparisons of anti-bacterial agents. Unfor-
tunately, Phase 3 clinical trial data for fourth generation 
ﬂ  uoroquinolones are not available for review in the public 
domain (per personal correspondence to both Allergan and 
Alcon Research LTC).
In anti-bacterial studies that are placebo-controlled, 
reviewers must also weigh slight reductions in duration of 
ocular symptoms against contributions to increasing bacterial 
resistance to anti-bacterial therapy. Finally, when comparing 
against gold standards, readers should be aware that MIC90 
(minimum inhibitory concentration required to inhibit 90% 
of bacterial isolates) values do not signiﬁ  cantly differ among 
ophthalmic ﬂ  uoroquinolones and are far exceeded in current 
drug delivery methods (see Kowalski et al 2005, for further 
discussion of this important issue).
Confounders
Reviewers of studies must be wary of potential confound-
ers that may inﬂ  uence published results. Confounders are 
sources of error that occur when a factor other than the 
exposure of interest affects the result of the study (Hatch 
1998). In other words, these are factors that have not been 
controlled for via study design and which may lead to faulty 
causation. Readers cannot be sure if the reported effect was a 
direct result of the study intervention or an indirect result of 
the confounder, especially when reported treatment effects 
are narrow.
Examples of potential confounders in ophthalmic studies 
include the concurrent use of Centrum® (Whitehall-Robins 
Healthcare, Madison, NJ, USA) multivitamin and mineral 
supplements with the study formulation in the Age-Related 
Eye Disease Study (AREDS 2001), allowance of verteporﬁ  n 
therapy before and during the pegaptanib Phase 3 trial for 
neovascular AMD (Gragoudas et al 2004), or the use of 
verteporﬁ  n therapy during the Phase 3 MARINA study of 
ranibizumab (Rosenfeld et al 2006).
In the case of the AREDS study, how can the reviewer be 
certain that the Centrum supplements were not responsible for 
the mild, reported treatment effect and not the study medica-
tion? In the cases of pegaptanib or ranibizumab can we be 
certain that the observed effect was due to the investigational 
medication or a delayed response to verteporﬁ  n (or, if the 
study medications are more effective, then what becomes 
the new gold standard?). If these potential confounders are 
not sufﬁ  ciently explained by the investigators, then readers 
are left to question the veracity of the reported conclusions 
found in the abstracts.
Study endpoints
A crucial factor to consider in all medical research is the 
deﬁ  nition of study endpoint. Since very few ophthalmic 
conditions are reported in terms of “cure rates” or “preven-
tion rates,” investigators must pre-determine endpoints for 
research with ﬁ  nite temporal limits. From the standpoint 
of study design, research endpoints should be succinctly 
deﬁ  ned, reproducible, and appropriate to the hypothesis. 
Literature reviewers must ask themselves “did the endpoint(s) 
answer the original question?” Failure to report results in 
terms of primary outcomes represents a failure of a study 
to provide meaningful clinical information, and calls into 
question the original study hypothesis. It is also helpful to 
see outcomes written in terms of null hypotheses, but often 
readers are left to deduce this for themselves.
More to the point, however, reviewers must ask them-
selves a more clinically-relevant question regarding a study, 
namely: does the study ask a clinically-useful question? If 
a pharmaceutical trial is addressing a clinical entity like 
bacterial conjunctivitis, which is described as a self-limiting 
condition, and which is difﬁ  cult to deﬁ  nitively diagnose 
without point-of-care testing, then perhaps it is more perti-
nent to question whether the self-limiting condition needs 
any active pharmaceutical agent at all, rather than assessing 
whether the medication resolves the condition. Even more 
basic to this discussion is the questions of whether there is 
any such thing as a ‘garden variety’ bacterial conjunctivitis. 
Although usually explicitly stated, there is another germane 
clinical question for readers to consider for an antibacterial 
ophthalmic medication: is in vitro data applicable to in vivo 
clinical settings? This is another test of external validity. 
These ideas are rarely discussed in ophthalmic anti-bacterial 
pharmaceutical trials, leaving the readers to wonder why.
Readers must also consider ﬁ  nancial implications of phar-
maceutical trials on their patients and society as a whole. Are 
the ﬁ  ndings signiﬁ  cant enough to justify the cost of switching 
to a new gold standard? As it remains incumbent upon all 
medical providers to consider medical costs for interventions, 
literature reviewers should be aware of the phenomenon of 
“latest-greatest” drugs. The assumption bias here is that the 
newest pharmaceutical agent on the market must somehow 
be the best. Clinically, readers need to ask more challenging 
questions of study reports, including whether the drug better 
than existing treatments and gold standards, or placebo.Clinical Ophthalmology 2008:2(2) 409
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This is especially important when the more inexpensive 
alternative may also be more efﬁ  cacious. Consider the pos-
sibility of mild ophthalmic corticosteroids for the palliative 
relief of the symptoms of allergic conjunctivitis. Olopatadine 
hydrochloride costs approximately  57 ($80) per 5 mL versus 
25 ($35) per 5 mL for generic olopatadine (available in 
the UK as Optanol®, but not yet available in the US). Then 
compare both of these to  14 ($20) per 5 mL for generic 
ﬂ  uorometholone. Two to four times as many patients can 
be treated with the same clinical outcome with the generic 
corticosteroid eye drop, however, to date, a direct comparison 
of these ophthalmic medications has not occurred.
Finally, medical providers should always think in terms 
of functional outcomes. Functional outcomes are those end-
points which address mortality and morbidity. Fortunately, 
few ophthalmic clinical trials need address mortality issues, 
but many ophthalmic conditions impinge on important issues 
of morbidity: vision loss and quality of life (Vu et al 2005). 
Speciﬁ  cally, can a patient undergoing the treatment perceive 
an “improvement” following the intervention? Although sub-
jective in origin, ophthalmic patients typically wish for their 
vision to improve back to reading/driving levels (in the cases of 
vitreo-retinal, lenticular, or corneal interventions, for example) 
or for their eyes to feel better (in the cases of conjunctivitides, 
uveitides, for example). Readers would always hope that study 
endpoints would be written to allow for functional improve-
ments that patients can appreciate.
A shortcoming of many retinal studies is that study 
endpoints are deﬁ  ned in terms of improvement via halving 
of the visual angle. While statistically signiﬁ  cant, there is 
considerable room for claims regarding clinical signiﬁ  cance. 
Few patients seem to rave about improvements from 20/200 
to 20/100 (three lines) on the Early Treatment Diabetic 
Retinopathy Study (ETDRS) visual acuity charts. While a 
statistical victory, such patients are still unable to drive or 
to read their mail without low vision magniﬁ  cation, and this 
calls into question the issues of both internal and external 
validations of study results. Pharmaceutical studies in pri-
mary open-angle glaucoma are fraught with the additional 
problem of a lack of early patient symptoms, making the 
realization of functional improvement even more difﬁ  cult 
for study investigators to address. This may continue to be a 
problem until the ophthalmic community can begin reporting 
ﬁ  ndings in terms of “cure rates” or “prevention rates.”
Conclusion
Clinical trial results that can withstand careful scrutiny 
by many readers may stand the test of time; however, 
immediate acceptance of conclusions found in abstracts may 
lead to erroneous generalization of study results to clinical 
populations. Only individual practitioners can evaluate the 
evidence for themselves, and the responsibility to do so 
remains incumbent upon them. When reviewing ophthalmic 
pharmaceutical trials, readers must consider the internal 
validity issues of patient selection, standards of comparison 
and study endpoints, and then determine if the study results 
are externally valid and can be applied to their own patient 
populations. The ﬁ  nal determination regarding a switch in 
clinical practice to a new gold standard should be based on 
individual review and not on other sources. It is the intent 
of this article to assist practitioners in their ongoing quest to 
provide the best clinical care for their patients.
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